Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $4,385 | $3,473 | $39 | $38 |
| - Cash | $311 | $159 | $1,643 | $1,248 |
| + Debt | $3,025 | $2,623 | $2,784 | $2,946 |
| Enterprise Value | $7,098 | $5,936 | $1,180 | $1,737 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$431 | -$397 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$6,277 | -$2,455 | -$2,691 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$6,870 | -$5,616 | -$3 | -$2 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.94 | -1 | -0.92 | -0.78 |
| % Growth | -94% | -8.7% | -17.9% | – |
| Operating Cash Flow | -$5,194 | -$2,231 | -$2 | -$2,775 |
| Capital Expenditures | -$5 | -$17 | $0 | -$104 |
| Free Cash Flow | -$5,199 | -$2,248 | -$2 | -$2,879 |